미만성 거대 B세포 림프종 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "미만성 거대 B세포 림프종" in Korean language version.

refsWebsite

Global rank Korean rank

14doi.org

2^nd place

3^rd place

14nih.gov

4^th place

3semanticscholar.org

11^th place

310^th place

1uptodate.com

3,771^st place

3,916^th place

doi.org

dx.doi.org

“A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project”. 《Blood》 89 (11): 3909–3918. June 1997. doi:10.1182/blood.V89.11.3909. PMID 9166827.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (January 2006). “Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001”. 《Blood》 107 (1): 265–276. doi:10.1182/blood-2005-06-2508. PMC 1895348. PMID 16150940.
Smith A, Howell D, Patmore R, Jack A, Roman E (November 2011). “Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network”. 《British Journal of Cancer》 105 (11): 1684–1692. doi:10.1038/bjc.2011.450. PMC 3242607. PMID 22045184.
Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A (March 2010). “The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research”. 《British Journal of Haematology》 148 (5): 739–753. doi:10.1111/j.1365-2141.2009.08010.x. PMC 3066245. PMID 19958356.
Casulo C, Friedberg J (2017). “Transformation of marginal zone lymphoma (and association with other lymphomas)”. 《Best Practice & Research. Clinical Haematology》 30 (1–2): 131–138. doi:10.1016/j.beha.2016.08.029. PMID 28288708.
Abuelgasim KA, Rehan H, Alsubaie M, Al Atwi N, Al Balwi M, Alshieban S, Almughairi A (March 2018). “Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature”. 《Journal of Medical Case Reports》 12 (1): 64. doi:10.1186/s13256-018-1612-4. PMC 5845776. PMID 29524963.
Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM (July 2018). “EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management”. 《American Journal of Hematology》 93 (7): 953–962. doi:10.1002/ajh.25112. PMID 29984868.
Nicolae A, Pittaluga S, Abdullah S, Steinberg SM, Pham TA, Davies-Hill T, Xi L, Raffeld M, Jaffe ES (August 2015). “EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment”. 《Blood》 126 (7): 863–72. doi:10.1182/blood-2015-02-630632. PMC 4536540. PMID 25999451.
Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ (November 2019). “Diffuse large B-cell lymphoma variants: an update”. 《Pathology》 52 (1): 53–67. doi:10.1016/j.pathol.2019.08.013. PMID 31735345. S2CID 208142227.
Shimada K, Hayakawa F, Kiyoi H (November 2018). “Biology and management of primary effusion lymphoma”. 《Blood》 132 (18): 1879–1888. doi:10.1182/blood-2018-03-791426. PMID 30154110.
Liu Y, Barta SK (May 2019). “Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment”. 《American Journal of Hematology》 94 (5): 604–616. doi:10.1002/ajh.25460. PMID 30859597.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (May 2016). “The 2016 revision of the World Health Organization classification of lymphoid neoplasms”. 《Blood》 127 (20): 2375–90. doi:10.1182/blood-2016-01-643569. PMC 4874220. PMID 26980727.
Akyurek N, Uner A, Benekli M, Barista I (September 2012). “Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab”. 《Cancer》 118 (17): 4173–4183. doi:10.1002/cncr.27396. PMID 22213394. S2CID 19134744.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, 외. (June 2005). “Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte”. 《Journal of Clinical Oncology》 23 (18): 4117–4126. doi:10.1200/JCO.2005.09.131. PMID 15867204. S2CID 23556248.

nih.gov

ncbi.nlm.nih.gov

“A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project”. 《Blood》 89 (11): 3909–3918. June 1997. doi:10.1182/blood.V89.11.3909. PMID 9166827.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (January 2006). “Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001”. 《Blood》 107 (1): 265–276. doi:10.1182/blood-2005-06-2508. PMC 1895348. PMID 16150940.
Smith A, Howell D, Patmore R, Jack A, Roman E (November 2011). “Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network”. 《British Journal of Cancer》 105 (11): 1684–1692. doi:10.1038/bjc.2011.450. PMC 3242607. PMID 22045184.
Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A (March 2010). “The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research”. 《British Journal of Haematology》 148 (5): 739–753. doi:10.1111/j.1365-2141.2009.08010.x. PMC 3066245. PMID 19958356.
Casulo C, Friedberg J (2017). “Transformation of marginal zone lymphoma (and association with other lymphomas)”. 《Best Practice & Research. Clinical Haematology》 30 (1–2): 131–138. doi:10.1016/j.beha.2016.08.029. PMID 28288708.
Abuelgasim KA, Rehan H, Alsubaie M, Al Atwi N, Al Balwi M, Alshieban S, Almughairi A (March 2018). “Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature”. 《Journal of Medical Case Reports》 12 (1): 64. doi:10.1186/s13256-018-1612-4. PMC 5845776. PMID 29524963.
Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM (July 2018). “EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management”. 《American Journal of Hematology》 93 (7): 953–962. doi:10.1002/ajh.25112. PMID 29984868.
Nicolae A, Pittaluga S, Abdullah S, Steinberg SM, Pham TA, Davies-Hill T, Xi L, Raffeld M, Jaffe ES (August 2015). “EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment”. 《Blood》 126 (7): 863–72. doi:10.1182/blood-2015-02-630632. PMC 4536540. PMID 25999451.
Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ (November 2019). “Diffuse large B-cell lymphoma variants: an update”. 《Pathology》 52 (1): 53–67. doi:10.1016/j.pathol.2019.08.013. PMID 31735345. S2CID 208142227.
Shimada K, Hayakawa F, Kiyoi H (November 2018). “Biology and management of primary effusion lymphoma”. 《Blood》 132 (18): 1879–1888. doi:10.1182/blood-2018-03-791426. PMID 30154110.
Liu Y, Barta SK (May 2019). “Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment”. 《American Journal of Hematology》 94 (5): 604–616. doi:10.1002/ajh.25460. PMID 30859597.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (May 2016). “The 2016 revision of the World Health Organization classification of lymphoid neoplasms”. 《Blood》 127 (20): 2375–90. doi:10.1182/blood-2016-01-643569. PMC 4874220. PMID 26980727.
Akyurek N, Uner A, Benekli M, Barista I (September 2012). “Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab”. 《Cancer》 118 (17): 4173–4183. doi:10.1002/cncr.27396. PMID 22213394. S2CID 19134744.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, 외. (June 2005). “Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte”. 《Journal of Clinical Oncology》 23 (18): 4117–4126. doi:10.1200/JCO.2005.09.131. PMID 15867204. S2CID 23556248.

semanticscholar.org

api.semanticscholar.org

Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ (November 2019). “Diffuse large B-cell lymphoma variants: an update”. 《Pathology》 52 (1): 53–67. doi:10.1016/j.pathol.2019.08.013. PMID 31735345. S2CID 208142227.
Akyurek N, Uner A, Benekli M, Barista I (September 2012). “Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab”. 《Cancer》 118 (17): 4173–4183. doi:10.1002/cncr.27396. PMID 22213394. S2CID 19134744.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, 외. (June 2005). “Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte”. 《Journal of Clinical Oncology》 23 (18): 4117–4126. doi:10.1200/JCO.2005.09.131. PMID 15867204. S2CID 23556248.

uptodate.com

Freeman AS, Aster JS (2012). 〈Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma〉. Basow DS. 《UpToDate》. Waltham, MA: UpToDate.